NIB visits the Baltics’ first Gene Therapy Centre

Following the Board of Directors meeting in Vilnius, the members of the Board and the Bank’s management visited the NIB-financed Gene Therapy Centre just on the outskirts of Lithuania’s capital. This state-of-the-art facility is driving advancements in both research and manufacturing processes. Opened in September, the Centre further strengthens Lithuania’s rapidly growing life sciences sector. Currently contributing approximately 2.5% to the country’s GDP, the sector aims to double its share to 5% by 2030.

“This investment is more than just a building – it’s the first facility in the Baltics dedicated to the development and manufacturing of advanced gene therapy drugs and a major milestone in the development of BIO CITY, our long-term vision to create Europe’s largest biotechnology hub,” said Prof. Vladas Algirdas Bumelis, CEO of Celltechna. “We are proud to be working together with NIB to drive scientific innovation, strengthen the life sciences sector, and support economic growth across the Nordic-Baltic region.”

According to the Chair of NIB’s Board of Directors Merle Wilkinson, the project is a flagship for both Lithuania and NIB. “It creates new high-value-added workplaces and builds competitive advantage for Lithuania’s economy in the long term. With these kinds of partnerships, we also increase resilience of the economies of our Nordic-Baltic region.”

Watch the video: